OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 3.

Table. 3.

Mean eGFR values calculated using each combination of reagents and equations according to groups based on Gentiancys values

Reagent Equation Mean eGFR values (mL/min/1.73 m2) according to groups based on Gentiancys values* Total

Q1 (N=37) Q2 (N=37) Q3 (N=37) Q4 (N=37)
Gentiancys Gentiancys, mean ± SD (range), mg/L 3.69 ± 1.68 (1.98–7.51) 1.46 ± 0.20 (1.23–1.83) 1.04 ± 0.10 (0.80–1.19) 0.69 ± 0.09 (0.52–0.80) 1.72 ± 1.44 (0.52–7.51)
CKD-EPIcys 17.4 ± 9.2 47.3 ± 9.5 73.3 ± 11.1 109.7 ± 10.9 62.2 ± 35.7
Gentianeq (%diff, P) 16.6 ± 8.9 47.7 ± 9.2 77.3 ± 11.6 141.0 ± 27.3 70.7 ± 48.8
(−5.2, P < 0.001) (1.1, P < 0.001) (5.6, P < 0.001) (27.8, P < 0.001) (7.2, P < 0.001)
CAPAeq (%diff, P) 17.3 ± 10.3 48.0 ± 8.2 71.3 ± 9.0 115.9 ± 19.4 63.4 ± 38.4
(−6.9, P < 0.001) (2.2, P < 0.001) (−2.4, P < 0.001) (5.6, P < 0.001) (−0.4, P < 0.001)
FASeq (%diff, P) 22.6 ± 10.2 50.3 ± 8.8 68.9 ± 10.6 105.8 ± 20.8 62.1 ± 33.4
(38.9, P < 0.001) (7.5, P < 0.001) (−5.6, P < 0.001) (−3.8, P < 0.001) (9.3, P < 0.001)
EKFCcys (%diff, P) 24.9 ± 10.6 54.4 ± 8.5 75.8 ± 9.3 116.3 ± 18.6 67.8 ± 35.6
(53.8, P < 0.001) (16.6, P < 0.001) (−3.3, P < 0.001) (5.2, P < 0.001) (19.6, P < 0.001)
Rochecys Rochecys, mean ± SD (range), mg/L 3.55 ± 1.57 (1.96–6.70) 1.45 ± 0.20 (1.20–1.85) 1.08 ± 0.09 (0.92–1.20) 0.77 ± 0.08 (0.63–0.92) 1.71 ± 1.35 (0.63–6.70)
CKD-EPIcys (%diff, P) 18.2 ± 9.8 47.7 ± 9.2 69.9 ± 9.7 102.9 ± 12.2 59.9 ± 32.9
(5.0, P < 0.001) (1.0, P < 0.001) (−4.7, P < 0.001) (−6.1, P < 0.001) (−1.2, P < 0.001)
CAPAeq (%diff, P) 18.3 ± 10.9 48.4 ± 8.0 68.3 ± 7.8 101.2 ± 14.4 59.3 ± 32.3
(0.1, P < 0.001) (3.1, P < 0.001) (−6.5, P < 0.001) (−7.7, P < 0.001) (−2.8, P < 0.001)
FASeq (%diff, P) 23.4 ± 10.6 50.7 ± 8.9 66.5 ± 9.8 94.1 ± 17.6 58.8 ± 28.6
(44.1, P < 0.001) (8.4, P < 0.001) (−8.9, P < 0.001) (−14.4, P < 0.001) (7.3, P < 0.001)
EKFCcys (%diff, P) 25.8 ± 11.1 54.7 ± 8.4 73.0 ± 8.3 103.4 ± 14.9 64.2 ± 30.3
(59.6, P < 0.001) (16.9, P < 0.001) (−0.4, P < 0.001) (−6.4, P < 0.001) (17.4, P < 0.001)

*According to previously recorded Gentiancys values, participants were divided into four groups: Q1 (>1.98 mg/L), Q2 (1.22–1.98 mg/L), Q3 (1.21–0.80 mg/L), and Q4 (<0.80 mg/L). The %diff was calculated as (A−B)/B×100, where B is the eGFR value of CKD-EPIcys with Gentiancys. All groups showed significant differences (P<0.001) when using the Wilcoxon signed-rank analysis to compare the difference between each eGFR combination and CKD-EPIcys with Gentiancys.

Abbreviations: eGFR, estimated glomerular filtration rate; Gentiancys, Gentian cystatin C immunoassay; Rochecys, Tina-quant Gen.2 analysis; Gentianeq, equation of Gentian manufacturer; CKD-EPIcys, CKD-EPI cystatin C equation; CAPAeq, equation of Caucasian, Asian, pediatric, and adult participants; FASeq, equation of full age spectrum; EKFCcys, EKFC cystatin C equation; %diff, percent difference.

Ann Lab Med 2023;43:565~573 https://doi.org/10.3343/alm.2023.43.6.565

© Ann Lab Med